| Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer S Masoumi Moghaddam, A Amini, DL Morris, MH Pourgholami Cancer and Metastasis Reviews 31, 143-162, 2012 | 277 | 2012 |
| A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative … RE Kast, JA Boockvar, A Brüning, F Cappello, WW Chang, B Cvek, ... Oncotarget 4 (4), 502, 2013 | 201 | 2013 |
| The fruit essential oil of Pimpinella anisum exerts anticonvulsant effects in mice MH Pourgholami, S Majzoob, M Javadi, M Kamalinejad, GHR Fanaee, ... Journal of ethnopharmacology 66 (2), 211-215, 1999 | 181 | 1999 |
| Gene of the month: Interleukin 6 (IL-6) P Ataie-Kachoie, MH Pourgholami, DR Richardson, DL Morris Journal of clinical pathology 67 (11), 932-937, 2014 | 174 | 2014 |
| In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole MH Pourgholami, L Woon, R Almajd, J Akhter, P Bowery, DL Morris Cancer letters 165 (1), 43-49, 2001 | 171 | 2001 |
| Involvement of urokinasetype plasminogen activator system in cancer: An overview AH Mekkawy, MH Pourgholami, DL Morris Medicinal research reviews 34 (5), 918-956, 2014 | 161 | 2014 |
| Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer P Ataie-Kachoie, MH Pourgholami, DL Morris Cytokine & growth factor reviews 24 (2), 163-173, 2013 | 150 | 2013 |
| Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice M Hossein Pourgholami, Z Yan Cai, Y Lu, L Wang, D Lawson Morris Clinical Cancer Research 12 (6), 1928-1935, 2006 | 143 | 2006 |
| Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit [n] uril Y Zhao, DP Buck, DL Morris, MH Pourgholami, AI Day, JG Collins Organic & Biomolecular Chemistry 6 (24), 4509-4515, 2008 | 135 | 2008 |
| Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis MH Pourgholami, J Akhter, L Wang, Y Lu, DL Morris Cancer chemotherapy and pharmacology 55, 425-432, 2005 | 131 | 2005 |
| Evaluation of the anticonvulsant activity of the essential oil of Eugenia caryophyllata in male mice MH Pourgholami, M Kamalinejad, M Javadi, S Majzoob, M Sayyah Journal of ethnopharmacology 64 (2), 167-171, 1999 | 120 | 1999 |
| Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model L Noorani, M Stenzel, R Liang, MH Pourgholami, DL Morris Journal of nanobiotechnology 13, 1-12, 2015 | 106 | 2015 |
| Urokinase plasminogen activator system as a potential target for cancer therapy AH Mekkawy, DL Morris, MH Pourgholami Future Oncology 5 (9), 1487-1499, 2009 | 105 | 2009 |
| In vitro and in vivo inhibition of liver cancer cells by 1, 25-dihydroxyvitamin D3 MH Pourgholami, J Akhter, Y Lu, DL Morris Cancer letters 151 (1), 97-102, 2000 | 104 | 2000 |
| Diffuse malignant peritoneal mesothelioma–an update on treatment P Mirarabshahii, K Pillai, TC Chua, MH Pourgholami, DL Morris Cancer treatment reviews 38 (6), 605-612, 2012 | 103 | 2012 |
| p70 Ribosomal protein S6 kinase (Rps6kb1): an update F Bahrami-B, P Ataie-Kachoie, MH Pourgholami, DL Morris Journal of clinical pathology 67 (12), 1019-1025, 2014 | 102 | 2014 |
| Effect of cross-linking on the performance of micelles as drug delivery carriers: a cell uptake study Y Kim, MH Pourgholami, DL Morris, MH Stenzel Biomacromolecules 13 (3), 814-825, 2012 | 97 | 2012 |
| Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole SWL Chu, S Badar, DL Morris, MH Pourgholami Anticancer research 29 (10), 3791-3796, 2009 | 88 | 2009 |
| Pilot Study of Albendazole in Patients with Advanced MalignancyEffect on Serum Tumor Markers/High Incidence of Neutropenia DL Morris, JL Jourdan, MH Pourgholami Oncology 61 (1), 42-46, 2001 | 76 | 2001 |
| Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer MH Pourgholami, M Szwajcer, M Chin, W Liauw, J Seef, P Galettis, ... Cancer chemotherapy and pharmacology 65, 597-605, 2010 | 75 | 2010 |
